Evidence map›Paper›PMID 42666672›Full record

ReviewFrontiers in medicine2026

Fatty acid-binding protein 2 in inflammatory bowel disease: mechanistic insights and translational perspectives.

Shuhang Zhong, Kaishuo Lv, Xiaoqing Liu, Junru Zhou, Jiayu Ye, Zhiyu Yang

Abstract readReview
In one paragraph

Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shuhang ZhongDepartment of Gastroenterology and Hepatology, People's Hospital of Jiaozuo City, Jiaozuo, Henan, China.
Kaishuo LvDepartment of Gastroenterology and Hepatology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Xiaoqing LiuDepartment of Gastroenterology and Hepatology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Junru ZhouDepartment of Laboratory Medicine, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Jiayu YeDepartment of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA, United States.
Zhiyu YangDepartment of Gastroenterology and Hepatology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fatty acid-binding protein 2 (FABP2) is an intestine-specific cytoplasmic lipid chaperone with a molecular weight of approximately 14-15 kDa that plays a pivotal role in the uptake, intracellular trafficking, and metabolism of long-chain fatty acids. Emerging evidence indicates that FABP2 is not only a sensitive biomarker of intestinal mucosal injury but also may contribute to the pathogenesis and progression of IBD, potentially through the modulation of PPARγ signaling pathway, although the underlying mechanisms require further investigation. This review systematically summarizes the structural and functional characteristics of the fatty acid-binding protein (FABP) family members, with particular emphasis on the biological features of FABP2. We discuss the involvement of FABP2 in multisystem diseases and highlight its specific relevance in IBD. Furthermore, we summarize current evidence regarding the potential molecular mechanisms by which FABP2 may influence IBD, including its possible roles in intestinal barrier dysfunction, lipid metabolism, gut microbiota-host interactions, and its potential contribution to the attenuation of intestinal inflammation, possibly through regulation proliferation and differentiation of intestinal stem cells. Although the biological investigations of FABP2 in inflammatory bowel disease (IBD) have yielded promising findings, its clinical translation is still confronted with challenges such as the precise assessment of disease activity and the development of safe and effective targeted therapeutics. Collectively, this review provides a comprehensive reference for researchers and clinicians in the IBD field, highlighting the well-supported role of FABP2 as a diagnostic biomarker while discussing its potential as a therapeutic target, an area that warrants further mechanistic and clinical investigation.

Indexed as

biomarkerfatty acid-binding protein 2inflammatory bowel diseasemolecular mechanismstherapeutic target

Identifiers

PMID42666672
PMCPMC13523771

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.